Will combine GEMoaB's RevCAR technology platform with Intellia's genome editing technologies to discover and develop allogeneic cellular immunotherapies.
To leverage Carterra’s LSA platform to screen hundreds of antibodies in a few days as CoVIC seeks to find therapeutic candidates for COVID-19 in just weeks
Bill Enright, former CEO at Gaithersburg-based Altimmune, brings experience in progressing science research, and development through executive and management roles